EGFR and non-small cell lung carcinoma: A retrospective review of pemetrexed in the treatment of LM in patients with EGFR-mutated NSCLC demonstrated prolonged survival with pemetrexed use after the development of LM relative to no pemetrexed use (median 13.7 months vs. 4.0 months, p = 0.008).